Literature DB >> 34971077

The longest reported sibling survivors of a severe form of congenital myasthenic syndrome with the ALG14 pathogenic variant.

Yu Katata1, Saki Uneoka1, Naoya Saijyo1, Yu Aihara1, Takamitsu Miyazoe1, Shun Koyamaishi2, Yoshitsugu Oikawa1, Yuya Ito2,3, Yu Abe1,4, Yurika Numata-Uematsu1, Jun Takayama5,6,7, Atsuo Kikuchi1, Gen Tamiya5,6,7, Mitsugu Uematsu1, Shigeo Kure1.   

Abstract

Congenital myasthenic syndromes (CMS) is a group of diseases that causes abnormalities at the neuromuscular junction owing to genetic anomalies. The pathogenic variant in ALG14 results in a severe pathological form of CMS causing end-plate acetylcholine receptor deficiency. Here, we report the cases of two siblings with CMS associated with a novel variant in ALG14. Immediately after birth, they showed hypotonia and multiple joint contractures with low Apgar scores. Ptosis, low-set ears, and high-arched palate were noted. Deep tendon reflexes were symmetrical. They showed worsening swallowing and respiratory problems; hence, nasal feeding and tracheotomy were performed. Cranial magnetic resonance imaging scans revealed delayed myelination and cerebral atrophy. Exome sequencing indicated that the siblings had novel compound heterozygous missense variants, c.590T>G (p.Val197Gly) and c.433G>A (p.Gly145Arg), in exon 4 of ALG14. Repetitive nerve stimulation test showed an abnormal decrease in compound muscle action potential. After treatment with pyridostigmine, the time off the respirator increased. Their epileptic seizures were well controlled by anti-epileptic drugs. Their clinical course is stable even now at the ages of 5 and 2 years, making them the longest reported survivors of a severe form of CMS with the ALG14 variant thus far.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  ALG14; congenital disorders of glycosylation; congenital myasthenic syndrome; repetitive nerve stimulation test; whole-exome sequence

Mesh:

Year:  2021        PMID: 34971077     DOI: 10.1002/ajmg.a.62629

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  1 in total

1.  An in vitro assay for enzymatic studies on human ALG13/14 heterodimeric UDP-N-acetylglucosamine transferase.

Authors:  Chun-Di Wang; Si Xu; Shuai Chen; Zheng-Hui Chen; Neta Dean; Ning Wang; Xiao-Dong Gao
Journal:  Front Cell Dev Biol       Date:  2022-09-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.